
In US capital, Trump tariffs bite into restaurant profits
WASHINGTON : Brazilian coffee beans, French champagne and Chinese teas – drinks are a profit driver for US restaurants, but higher import costs have eaten into margins and fed into consumer prices in the three months since President Donald Trump unveiled sweeping global tariffs.
A stone's throw from the White House, a restaurant group that takes pride in dishing up fresh local meat and produce has found itself having to raise prices on its menus.
'The reality is, we have to pass along some of those to our guests,' said John Filkins, corporate beverage director at Clyde's Restaurant Group.
'Could be anywhere from 50 cents to US$1 on certain wines by the glass, or spirits, or some of our food menu items,' he told AFP.
'We've seen huge increases in coffee and teas, and we're beginning to see some of those increases in food, as well as paper products coming on through as well,' he added.
Clyde's, which opened in the 1960s in Washington, has more than a dozen restaurants in and around the US capital.
One of them is The Hamilton in downtown Washington, where drinks prices have ticked up.
While management has tried to limit increases, Filkins said this has been tough.
Businesses have encountered snarled supply chains and higher costs since Trump imposed fresh tariffs after returning to the presidency in January.
In April, the president unleashed his widest-ranging salvo, a 10% duty on imports from most trading partners.
This is expected to surge to higher levels for dozens of economies.
'Low cash, low margin'
Leaders like Filkins are eyeing a deadline next Wednesday when the steeper tariffs are due to kick in.
These are customised to each partner, with the level for EU products rising to 20% and that for Japanese goods jumping to 24% unless they strike deals to avert or lower the rates.
Filkins warned that the longer tariffs remain in place, the fewer small, independent distributors, importers and restaurants there might be.
'The hope is we don't see tariffs to the extent where we're seeing them any longer,' he added.
'Restaurants are, at the end of the day, typically low cash, low margin,' Filkins said.
A typical outfit probably runs 'in the single digits in terms of profit margin,' he noted.
This means that cutting out 10% to 15% of their profit for wine by the glass, for example, could prove a significant blow.
20%-30% hikes
Clyde's sources coffee beans from places like Brazil and Indonesia for its blends, while getting teas from India and China.
'Over the course of the last probably six months, we've seen about a 20% to 30% increase of that cost,' Filkins said.
This is partly because suppliers and distributors are not only paying the 10% tariff but forking out more due to exchange rates.
Imports from China face a 30% tariff currently even though Washington and Beijing have temporarily lowered tit-for-tat levies on each other's goods.
Without a deal, products from Indonesia face a 32% duty come Wednesday, and the rate for India spikes to 26%.
'For liquor, beer and wine, most of the wine we import comes from the EU,' Filkins said, noting the impact is biggest on products from France, Italy, Spain and Portugal so far.
Yet, his company is trying to hold off passing on additional costs entirely.
'Consumers are not comfortable spending more in the current climate,' said Filkins.
The world's biggest economy has fared well after the Covid-19 pandemic, helped by a solid labour market that allowed consumers to keep spending.
However, economic growth has slowed alongside hiring.
Economists are monitoring to see if tariffs feed more broadly into inflation this summer, and households become more selective with purchases.
With Trump's approach of announcing, adjusting and halting tariffs roiling financial markets and fueling uncertainty – forcing businesses to put investments on hold – Filkins hopes for an easing of levies.
'It's hard for all of us to forecast what's going to happen in the next eight days.
'We can't base all of our decisions on speculation,' said Filkins.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Malay Mail
2 hours ago
- Malay Mail
Indonesia says 19pc US tariff might kick in before August 1
JAKARTA, July 21 — Indonesia's chief economic minister Airlangga Hartarto said today that a 19 per cent tariff on Indonesian goods entering the United States could come into effect sooner than an August 1 deadline set by US President Donald Trump. Airlangga said the timing of the tariff depended on a joint statement expected soon between the two countries, which reached a trade deal last week that led to a reduction in the threatened US proposed tariff rate to 19 per cent from 32 per cent. The deal was one of only a handful reached so far by the Trump administration ahead of the August 1 negotiation deadline with numerous countries. — Reuters


Free Malaysia Today
3 hours ago
- Free Malaysia Today
Wall Street futures rise on trade hope, earnings kick into high gear
The S&P 500 and the Nasdaq reached new heights throughout the last week. (EPA Images pic) NEW YORK : Wall Street futures edged higher today, buoyed by prospects of trade deals between the US and its key partners, while the earnings season picked up pace with several industrial and tech firms set to report this week. Futures tracking the S&P 500 rose 16.5 points, or 0.26% at 5.51am, and Nasdaq 100 e-minis climbed 65 points, or 0.28%, hovering near all-time highs hit last week. Dow e-minis rose 110 points, or 0.25%. Investors scoured for more trade deals ahead of President Donald Trump's Aug 1 tariff deadline. He threatened to impose a 30% tariff on imports from Mexico and the EU after weeks of negotiations with the major US trading partners failed to reach a comprehensive deal. Trump has sent letters to other trading partners, including Canada, Japan and Brazil, setting blanket tariff rates ranging from 20% to 50%. Commerce secretary Howard Lutnick's remarks yesterday, however, offered some optimism as he expressed confidence over striking a trade deal with the EU. The S&P 500 and the Nasdaq reached new heights throughout the last week as investors largely overlooked Trump's shifting tariff rhetoric in favour of stronger economic data and a solid start to the earnings season. The blue-chip Dow was 1.64% away from its all-time high. Of the 59 S&P 500 companies that have reported quarterly earnings this season, 81.4% have surpassed Wall Street's earnings expectations, compared with a long-term average of 67.1%, according to LSEG data as of Friday. All eyes will be on marquee companies such as Alphabet and Tesla later this week, as they kick off earnings for the so-called 'Magnificent Seven' stocks, which could influence the overall trajectory of Wall Street. Shares of Tesla and Alphabet were up 1.4% and 0.8% in premarket trading, respectively. Meanwhile, Verizon edged up 0.7% ahead of its results. The week is light on the economic data front, with only notable indicators being weekly jobless claims figures and the July business activity report on Thursday. Federal Reserve (Fed) chair Jerome Powell's comments tomorrow will be closely watched for clues on the central bank's future monetary policy stance. Traders have largely ruled out a July rate cut, and are pricing in an about 60% chance of a September reduction, as per CME Group's FedWatch tool. Ethereum-linked companies Bitmine Immersion Technologies, Gamesquare Holdings, BTCS and Sharplink Gaming advanced between 4.2% and 10.1% as Ether traded near its highest level this year after Trump signed into law a bill regulating stablecoins in the US.


Malay Mail
8 hours ago
- Malay Mail
IVD Medical Holding Limited (01931.HK): Officially launched the application for the US stablecoin license and accelerated the landing of the IVDNewCo Exchange ecosystem
HONG KONG SAR - Media OutReach Newswire - 21 July 2025 – IVD Medical Holding Limited( - Forward-looking layout of the historical opportunity of the US "Genius Act", the IVDD stablecoin plan is gathering momentum to set sail and build a new global infrastructure for medical innovative drugs RWA!In the wave of deep integration of global digital finance and medical innovation, IVD Medical Holding Limited( took the lead in building the "NewCo+RWA" Web3 exchange ecosystem (IVDNewCo Exchange) with the construction of medical innovative drugs high-tech assets as the core and the supporting stablecoin "IVDDollar" (IVDD) plan as the core strategy, leading the digital revolution of global medical innovation July 20, 2025, the Board of Directors is pleased to announce that the US subsidiary carrying the Group's aforementioned core strategic mission has landed, and the IVDNewCo Exchange ecosystem has officially landed on the international financial stage. The company released the latest announcement today, officially announcing two milestones: the US wholly-owned subsidiary IVD GROUP INC. has completed registration, and the Group has officially started the process of submitting a stablecoin license application to the US regulator through the subsidiary; at the same time, the Web3 exchange ecosystem with medical innovative drug NewCo assets as the core - IVDNewCo Exchange and its supporting stablecoin IVDD have entered a substantive strategic move not only marks the Group's leading position in the field of compliant digital finance for medical innovative drugs, but also heralds a revolutionary breakthrough in the global medical asset liquidity and value conversion July 18, 2025, local time, US President Trump signed the "Guidance and Establishment of the United States Stablecoin National Innovation Act" (hereinafter referred to as the "Genius Act") at the White House, establishing the legal status of stablecoins as "digital dollars". The implementation of this bill, together with the Stablecoin Ordinance of the Hong Kong Special Administrative Region, which will take effect on August 1, forms a regulatory synergy between the East and the West, and jointly builds the compliance cornerstone of the global stablecoin report of the China Banking Research Institute pointed out that currently 99% of the world's stablecoins are anchored to US dollar assets, and US Treasury bonds have become the core choice of stablecoin reserve assets due to their low risk and high liquidity. In this context, the Group proactively laid out the application for the US stablecoin license, and on July 20 officially announced that the US subsidiary had initiated the process of submitting application materials to regulatory agencies such as the US SEC and CFTC, becoming one of the very few listed companies in the Hong Kong stock market that has completed the "Hong Kong + US" dual hub compliance architecture strategic layout of the Group is deeply in line with the global regulatory trend. By establishing the US subsidiary IVD GROUP INC., we not only meet the strict requirements of the "Genius Act" for 100% reserve asset coverage and independent auditing of stablecoin issuers, but also rely on the sandbox mechanism of the Hong Kong "Stablecoin Ordinance" to build a cross-regional regulatory endorsement system. This dual hub model provides the IVDNewCo Exchange ecosystem with globally rare compliant liquidity support, enabling the Group to establish a first-mover advantage in the "Hong Kong Stock Stablecoin Concept Sector".The core breakthrough of the IVDNewCo Exchange ecosystem lies in the deep integration of Web3 technology and medical innovative drug assets. Relying on the commercial network covering 1,674 tertiary hospitals in China and the ability to acquire high-quality NewCo assets around the world, the Group has created the world's first RWA (real world asset) tokenization platform focusing on medical innovative drugs. The platform achieves the following innovations through blockchain technology:1). Asset tokenization: converting innovative drug assets such as ADC drugs, bi-antibody therapy, and cell gene therapy in the clinical stage into tradable and divisible digital certificates to break through the liquidity bottleneck of traditional medical assets;2). Compliance financial infrastructure: establish an underlying architecture to support the issuance, trading and settlement of IVDD stablecoins, ensuring that each $1 stablecoin corresponds to ultra-short-term U.S. Treasury bonds and other low-risk assets, meeting the U.S. SEC's "1:1 redeemable" requirements;3). Coin-stock linkage mechanism: coordinate with Nasdaq's dual primary listing plan to explore the compound value creation model of "digital assets + traditional equity" to attract two-way inflows of traditional medical capital and crypto-native implementation of this technical architecture has been strongly supported by industry data. Public information shows that the current global innovative drug market has exceeded US$1.2 trillion, and China accounts for 6% of the market with a scale of RMB 450 billion, with an annual compound growth rate of 20.3%. Through the RWA platform, the Group expects to significantly improve the financing efficiency of innovative drug assets, while lowering the entry threshold for investors, allowing small and medium-sized investors around the world to participate in the medical innovation field that was originally limited to institutional Group's strategic advancement has always followed the three-dimensional path of "regulatory compliance-technological innovation-ecological synergy". In the United States, IVD GROUP INC.'s license application strictly follows the requirements of the Genius Act for reserve asset transparency, anti-money laundering (AML) and network security. Its technical system has passed a third-party security audit to ensure that smart contracts are free of loopholes; in Hong Kong, the Group will actively promote participation in the HKMA's stablecoin sandbox program to test reserve asset management and cross-border payment scenarios, laying the foundation for license importantly, the implementation of the IVDNewCo Exchange ecosystem is reshaping the value chain of innovative medical drugs. Under the traditional model, the research and development of innovative drugs requires a cycle of up to 10 years, and 80% of the funds are concentrated in the clinical stage. Through the RWA platform, the Group can monetize clinical-stage assets in advance, provide pharmaceutical companies with low-cost financing channels, and provide investors with dynamic returns linked to the progress of drug development. For example, an ADC drug in Phase II clinical trials can attract global capital participation through tokenization, and its development progress data will be uploaded to the chain in real time to ensure that investors' rights and interests are transparent and Group's strategic initiatives have attracted widespread attention from the capital market and the industry. After the announcement on the 17th, IVD Medical's share price opened sharply higher on the 18th, closing at HK$2.95, up 20.41% throughout the day, with a turnover exceeding HK$9.4886 million and a market value of HK$4.783 billion. Behind the market data is investors' strong confidence in the cross-border integration of "NewCo+RWA+stablecoin".Looking ahead, the Group will continue to deepen the three strategic directions of compliance expansion, technology deepening and ecological integration. Against the backdrop of the global low interest rate environment and the surge in demand for medical innovation, it will use Web3 technology as a bridge to connect traditional medical capital and digital financial innovation. We firmly believe that through compliance layout and technological innovation, the IVDNewCo Exchange ecosystem will become a value amplifier for global innovative medical drug assets, creating a win-win situation for patients, pharmaceutical companies and #IVDMedicalHoldingLimited The issuer is solely responsible for the content of this announcement.